Both NRL and CRX have been shown to be required for tumor maintenance in Group 3 MB39 as well as defining Group 3 tumor identity.40 Additionally, ENO1 which has been shown to promote tumorigenesis in multiple types of cancer through the activation of the PI3K/AKT pathway,41 was upregulated in early Group 3 tumor cells. This evidence concerns the gene ENO1 and cancer.